Kirin Settles Suit Vs. Geron Over Cancer Vaccine Development Rights
The lawsuit has been dismissed, and the out-of-court settlement does not involve any payment by either party, Geron said in a statement.
There will be no effect on the licensing agreement between Geron and Merix Bioscience, and Kirin has subsequently entered into a global partnership with Merix for research and development activity relating to cancer therapies.
Kirin will make a $5 million investment to buy a...
To view the full article, register now.